Please use this identifier to cite or link to this item: doi:10.22028/D291-41037
Volltext verfügbar? / Dokumentlieferung
Title: Outcome of two patients with bilateral nephroblastomatosis/Wilms tumour treated with an add-on 13-cis retinoic acid therapy - Case report
Author(s): Friesenbichler, Waltraud
Krizmanich, Wolfgang
Lakatos, Karoly
Attarbaschi, Andishe
Dworzak, Michael
Amann, Gabriele
Furtwängler, Rhoikos
Graf, Norbert
Kager, Leo
Language: English
Title: Pediatric Hematology and Oncology
Volume: 35
Issue: 3
Publisher/Platform: Taylor & Francis
Year of Publication: 2018
Free key words: 13-cis retinoic acid
nephroblastomatosis
nephrogenic rest
retinoic acid
Wilms tumour
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Although the fate of nephrogenic rests varies, they are known to be precursors of Wilms tumour. Thus, nephrogenic rests require adequate treatment to prevent malignant transformation. We added 13-cis retinoic acid to the standard chemotherapy with vincristine and actinomycin-D in two patients with bilateral nephrogenic rests/nephroblastomatosis. Patient 1 also had a history of Wilms tumour. 46 (patient 1) and 81 (patient 2) months after end of treatment, both patients show stable conditions with no signs of relapse or progressive disease. Our observation supports further investigation of retinoic acid in patients with nephrogenic rests and nephroblastomatosis.
DOI of the first publication: 10.1080/08880018.2018.1515284
URL of the first publication: https://www.tandfonline.com/doi/full/10.1080/08880018.2018.1515284
Link to this record: urn:nbn:de:bsz:291--ds-410379
hdl:20.500.11880/36832
http://dx.doi.org/10.22028/D291-41037
ISSN: 1521-0669
0888-0018
Date of registration: 10-Nov-2023
Faculty: M - Medizinische Fakultät
Department: M - Pädiatrie
Professorship: M - Prof. Dr. Norbert Graf
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
There are no files associated with this item.


Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.